PARP Inhibitors for the Treatment of Ovarian Cancer - Gottfried Konecny, MD | UCLAMDChat
10 Bekeken
• 07/08/23
0
0
insluiten
administrator
abonnees
UCLA oncologist Gottfried Konecny, MD, gives an overview of the PARP inhibitors olaparib, niraparib, and rucaparib, which have been approved for the treatment of ovarian cancers and how to proactively plan for and manage treatment-related toxicities. #UCLAMDChat
Laat meer zien
Facebook Reacties
SORT BY-
Top Reacties
-
Laatste Reacties